Herbalife Nutrition Ltd., a global leader in nutrition and wellness, today announced an agreement to acquire Bioniq, a London-based company specializing in personalized supplements based on individual blood biomarkers and health data. The transaction, valued at up to $150 million, is expected to close in the second quarter of 2026, pending regulatory approvals.

Under the terms of the agreement, Herbalife will pay $55 million over five years, including $10 million at closing, with up to $95 million in additional performance-based payments.

Founded in 2019, Bioniq has developed a unique platform that combines blood test results, lifestyle inputs, and a proprietary biomarker database to deliver tailored nutrient formulations. Unlike standard supplementation, Bioniq’s approach aims not only to correct nutrient deficiencies but also to optimize micronutrient levels over time, adapting as users’ biological markers evolve.

“Bioniq represents the future of personalized nutrition,” said Herbalife CEO Stephan Gratziani. “By combining Bioniq’s technology with our Pro2col platform and global distributor network, we are expanding our ability to deliver personalized wellness solutions at scale.”

Bioniq’s founder, Vadim Fedotov, added, “We’re not a medical company; our mission is to help people optimize their performance and health, supporting longevity and overall wellbeing.”

Bioniq has already attracted a broad consumer base, including elite athletes such as global soccer star Cristiano Ronaldo, who became an investor in 2024. The company has created personalized formulas for hundreds of thousands of customers and has built one of the largest personalized nutrition datasets globally.

The acquisition also provides Herbalife with the option to acquire Bioniq LAB, a platform focused on small molecules and peptides, positioning the company to explore next-generation longevity interventions.

Bioniq’s products are expected to be launched through Herbalife’s distributor network in select European and U.S. markets later this year, with plans for further international expansion.